The goal of this clinical trial is to learn if antibiotics can prevent the formation of fistula-in-ano after incision and drainage of a first time of perianal abscess in adults. A perianal abscess is a collection of infected fluid near the anus. A Fistula-in-ano is an abnormal tunnel that can form between the anal canal and the skin after an abscess.
The main questions it aims to answer are:
Does taking antibiotics after incision and drainage of a perianal abscess lower the chance of developing a Fistula-in-ano? What medical problems or side effects do participants have after taking antibiotics or not taking antibiotics?
Researchers will compare participants who recieve antibiotics after abscess drainage with paticipants who do not recieve antibiotics after abscess drainage, to see if antibiotics lower the chance of developing a Fistula-in-ano.
Participants will:
Be randomly assigned to recieve antibiotics for 7 days after abscess incision and drainage or to not recieve antibiotics after abscess incision and drainage.
Attend follow-up clinic visits after incision and drainage as part of their standard of care.
Complete follow-up phone call about 12 months after incision and drainage. Allow the study team to review their medical record for abscess treatment, symptoms, recurrence, fistula-in-ano formation, additional procedures, and antibiotics side effects.

Start Date03 Aug 2026

Sponsor / Collaborator

University of Illinois

NCT07451171

/ RecruitingPhase 2IIT

A Phase II Trial to Prevent Linear Growth Stunting and Malnutrition in Impoverished Children From a Low-Income Country by Treating Small Intestine Bacterial Overgrowth

The purpose of this Phase IIa study is to identify the most effective antibiotic regimen to treat small intestine bacterial overgrowth (SIBO) in impoverished Bangladeshi children.

Start Date18 Apr 2026

Sponsor / Collaborator

University of Virginia

[+3]

ACTRN12626000287336

/ Not yet recruitingNot ApplicableIIT

Urinary amoxicillin-clavulanate concentrations in healthy female volunteers: Cross-over dosing study and validation of a preclinical bladder infection model

Start Date01 Apr 2026

Sponsor / Collaborator

Monash University

[+1]

100 Clinical Results associated with Amoxicillin/Clavulanate Potassium

100 Translational Medicine associated with Amoxicillin/Clavulanate Potassium

100 Patents (Medical) associated with Amoxicillin/Clavulanate Potassium

3,832

Literatures (Medical) associated with Amoxicillin/Clavulanate Potassium

01 Dec 2026·BRAZILIAN JOURNAL OF MICROBIOLOGY

Occurrence, antimicrobial resistance and molecular characterization of Salmonella spp. from broiler chickens in Northern Algeria

Article

Author: Khelifi Touhami, Nadjet Amina ; Ouchene, Nassim ; Boumahdi Merad, Zoubida ; Messai, Chafik Redha ; Salhi, Omar ; Cartelo, Leila Amel

Salmonella spp. are major zoonotic pathogens associated with poultry, representing a significant public health concern due to their role in foodborne infections and the growing emergence of antimicrobial resistance. This study aimed to investigate the prevalence, antimicrobial resistance patterns, and resistance/virulence genes of Salmonella spp. isolated from broiler chickens in the Boumerdès region, Algeria. A total of 110 liver and spleen samples were collected from broilers at a local slaughterhouse between November 2023 and November 2024. Isolation and identification were performed using standard microbiological methods, serotyping, and PCR for resistance and virulence genes. Ten Salmonella strains (9.09%) were recovered, with S. Kentucky (60%) and S. Enteritidis (40%) as the predominant serovars. Antimicrobial susceptibility testing revealed high resistance to nalidixic acid (100%), ciprofloxacin (100%), nitrofuran (80%), and tetracycline (80%), while low resistance was observed against amoxicillin-clavulanic acid (20%), and aminoglycosides (≤ 10%)and sensitivity of 100% for colistin and cefotaxime. All isolates exhibited multidrug resistance (MDR) with sevendistinct resistance profiles (MARI: 0.2-0.6). Phenotypic testing showed no extended-spectrum β-lactamase (ESBL) production. PCR analysis confirmed the universal presence of the virulence gene invA in all isolates, while no blaCTX-M or qnrA genes were detected. In conclusion, Salmonella spp. isolated from poultry in Boumerdès showed worrying resistance to multiple antibiotic classes, including quinolones and tetracyclines, reflecting the impact of uncontrolled antimicrobial use in poultry farming. The detection of MDR strains highlights the urgent need for improved biosecurity, prudent antimicrobial stewardship, and the implementation of a One Health approach to mitigate risks to both animal and human health.

01 Aug 2026·VETERINARY RESEARCH COMMUNICATIONS

Curcumin shows promise as an adjunct in changing β-lactam susceptibility status of canine multidrug-resistant Staphylococcus pseudintermedius: an in vitro study

Article

Author: Byun, William ; Boyd, Megan ; Richman, Austin ; Santoro, Domenico

Methicillin-resistant Staphylococcus pseudintermedius (MRSP) has become increasingly widespread in veterinary medicine, with a reported prevalence of up to 40.5% in dogs with pyoderma. Previous studies have shown that curcumin derived from turmeric (Curcuma longa L.) exhibits a synergistic effect when combined with β-lactam antibiotics, fluoroquinolones, tetracyclines, or vancomycin against strains of Staphylococcus aureus, including both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) isolates. Thus, the purpose of this study was to determine whether curcumin (500 µg/mL), in combination with oxacillin, amoxicillin-clavulanate, clindamycin, or doxycycline, could improve the susceptibility status of each antibiotic against multidrug-resistant Staphylococcus pseudintermedius (MDR-SP). Clinical isolates collected from dogs with MDR-SP pyoderma were tested against each antibiotic at their respective Clinical and Laboratory Standards Institute resistant, intermediate, and susceptible concentrations, in the presence or absence of curcumin. An ATCC methicillin-susceptible S. pseudintermedius reference strain (ATCC 49444) was included as an internal quality control. Exact McNemar test was used to assess paired isolate-level comparisons and a value of p < 0.05 was considered significant. A significant shift toward susceptibility was observed when curcumin was combined with oxacillin at the resistant (p = 0.001) and the susceptible (p < 0.0001) concentrations and with amoxicillin-clavulanate at the resistant (p = 0.002) and intermediate (p = 0.0078) concentrations. Amoxicillin-clavulanate at the susceptible concentration when combined with curcumin was not significant (p = 0.0625). Curcumin did not significantly alter the susceptibility status of clindamycin or doxycycline at any of the tested concentrations. Bactericidal concentrations were not observed at the tested concentrations. These results suggest that curcumin may potentiate the efficacy of select β-lactam antibiotics against MDR-SP, supporting curcumin as a potential β-lactam adjuvant against MDR-SP in vitro and warranting further evaluation.

01 Jul 2026·JOURNAL OF INFECTION

Exposure to antibiotics with anaerobe coverage in later life is associated with higher enteric pathobiont carriage

Article

Author: Rogers, Geraint B ; Vasil, Egi ; Papanicolas, Lito E ; Shoubridge, Andrew P ; Taylor, Steven L ; Miller, Sophie J

OBJECTIVES:

Infections involving enteric bacteria commonly cause hospitalisation and death in long-term residential aged care (LTC) populations. The risk of such infections has been linked with antibiotic-associated depletion of gut anaerobic commensals and the resulting increase in asymptomatic carriage of gut pathobionts. We sought to determine how antibiotic characteristics, particularly activity against anaerobes, influence pathobiont prevalence in LTC residents.

METHODS:

Stool samples from 164 LTC residents (median age: 87.9 years, interquartile range: 81.3-93.0 years) underwent metagenomic analysis. Associations between prior antibiotic exposures (categorised according to anaerobe coverage and type) and gut microbiome characteristics were explored using multivariable models.

RESULTS:

Of the 164 participants, 138 (84.1%) carried at least one enteric pathobiont. Compared to those with no prior antibiotic exposure, treatment with anaerobe covering (EAC) antibiotics was associated with higher rates of pathobiont carriage (β=1.36, P=0.010) and higher overall pathobiont relative abundance (β=3.53, P=0.013). In contrast, exposure to antibiotics with limited anaerobe coverage (LAC) showed no such associations. Investigation of commonly prescribed EAC and LAC antibiotics (amoxicillin-clavulanate and cefalexin, respectively) were consistent with these findings, with higher detection (β=1.60, P=0.007) and relative abundance (β=3.32, P=0.039) of pathobiont species in amoxicillin-clavulanate recipients. Pathobionts with greater representation included both species with inherent resistance (i.e. Enterococcus faecium) and sensitivity (i.e. Klebsiella pneumoniae) to amoxicillin-clavulanate.

CONCLUSIONS:

Antibiotics that deplete commensal anaerobes are associated with pathobiont prevalence in the gut, even where pathobiont species are sensitive to the administered antibiotic. Off-target disruption of commensal anaerobes should be considered when selecting antibiotic treatments, particularly for LTC individuals.

140

News (Medical) associated with Amoxicillin/Clavulanate Potassium

16 Jul 2026

·allsci.com

Shionogi seeking to expand Fetroja use into pediatric settings

Japan-based Shionogi & Co., Ltd. said the US FDA has accepted a Supplemental New Drug Application (sNDA) for cefiderocol (Fetroja), seeking to extend the antibiotic’s use to pediatric patients as young as 26 weeks of gestational age with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) and complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Gram-negative organisms. The filing, submitted by the New Jersey arm of Shionogi, moves the Fetroja pediatric FDA approval process into formal review, with the FDA setting a PDUFA action date of February 23, 2027. Fetroja is currently approved in the US only for adults with these infections; the sNDA, if cleared, would make it one of the few novel antibiotics with a labeled indication for pediatric HABP/VABP. The filing addresses a gap that has persisted since cefiderocol’s 2019 approval. Companies developing antibiotics for multidrug-resistant Gram-negative bacterial infections treatment have historically prioritized adult registration trials, leaving clinicians to use these agents off-label in children based on extrapolated dosing. The World Health Organization flagged this gap explicitly, adding cefiderocol to its 2023 PAediatric Drug Optimization priority list, which identifies medicines urgently needed for children where dosing, safety, and formulation data are lacking. Pediatric serious infections caused by drug-resistant Gram-negative bacteria, including carbapenem-resistant Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa, present a narrower set of treatment options than in adults. Several newer beta-lactam/beta-lactamase inhibitor combinations, including ceftazidime-avibactam and ceftolozane-tazobactam, hold pediatric approvals for cUTI and complicated intra-abdominal infections but not for HABP/VABP. Others, such as imipenem-cilastatin-relebactam and meropenem-vaborbactam, remain restricted to adults across all indications. If the sNDA is cleared, cefiderocol would become one of the only novel antibiotics with a dedicated pediatric label covering hospital-acquired and ventilator-associated pneumonia, a niche where clinicians currently rely on carbapenems or off-label use of newer agents. Shionogi’s pursuit of this indication is also tied to broader government-backed antimicrobial resistance efforts. The expansion work is supported by an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) under Project BioShield, a program initially funded at $119 million with multiyear options worth up to $482 million. That contract also funds a US manufacturing site for Fetroja and work extending the antibiotic against biothreat pathogens including Burkholderia pseudomallei and Yersinia pestis, indicating the pediatric filing sits within a wider federal push to secure domestic supply of drugs effective against resistant and biothreat organisms. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

Drug ApprovalQualified Infectious Disease Product

16 Jun 2026

·www.biospace.com

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets

Agreement expands access to XACDURO ® for patients with serious Acinetobacter baumannii-calcoaceticus complex (Acinetobacter) infections across South and Central America, the Caribbean, Russia and CIS countries (following applicable regional regulatory approvals) The rate of carbapenem resistant -Acinetobacter in these geographies exceeds 70% 1,2 representing substantial unmet need WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that it has entered into an exclusive distribution and licensing agreement with Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, for the development and commercialization of XACDURO ® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use, in South and Central America, the Caribbean, Russia and Commonwealth of Independent States (CIS) countries. In the United States, XACDURO ® is approved and indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter). Acinetobacter is a significant public health concern and is classified as a “critical threat” pathogen in World Health Organization global bacterial priority pathogens list 3 . Under the terms of the agreement, Dr. Reddy’s will be responsible for development, regulatory and commercialization activities in the licensed territory. Innoviva Specialty Therapeutics will retain rights to XACDURO in all unlicensed territories and is eligible to receive an upfront payment, regulatory and commercial milestone payments, and tiered royalties on net sales in the licensed territory. “This agreement reflects our ongoing commitment to addressing antimicrobial resistance by expanding access to important therapeutics for patients and healthcare systems facing serious, difficult-to-treat infections,” said Patricia Drake, Chief Commercial Officer of Innoviva Specialty Therapeutics. “Dr. Reddy’s brings strong regional capabilities and experience in infectious disease treatments, and we believe this partnership provides a practical path to broaden XACDURO’s global reach while maintaining our focus on disciplined execution.” XACDURO is the first and only antibiotic approved in the United States in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex ( Acinetobacter ). Acinetobacter infections remain a significant global health challenge, particularly in hospital settings where resistant pathogens can limit available treatment options. The FDA approved XACDURO in May 2023. About XACDURO ® XACDURO ® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use, is a combination of sulbactam, a beta-lactam antibacterial, and durlobactam, a beta-lactamase inhibitor, approved in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex ( Acinetobacter ). XACDURO is not indicated for the treatment of HABP/VABP caused by pathogens other than susceptible isolates of Acinetobacter . Current US FDA approved XACDURO ® INDICATION & USAGE Indication XACDURO ® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use is indicated in adults for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex. Limitations of Use XACDURO is not indicated for the treatment of HABP/VABP caused by pathogens other than susceptible isolates of Acinetobacter baumannii-calcoaceticus complex. Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of XACDURO and other antibacterial drugs, XACDURO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. IMPORTANT SAFETY INFORMATION Contraindications : XACDURO is contraindicated in patients with a history of known severe hypersensitivity to the components of XACDURO or other beta-lactam antibacterial drugs. Warnings and Precautions: Hypersensitivity was observed in patients treated with XACDURO in clinical trials. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterial drugs. Before initiating therapy with XACDURO, careful inquiry should be made concerning previous hypersensitivity reactions to carbapenems, penicillins, cephalosporins, other beta lactams, and other allergens. If an allergic reaction occurs, discontinue XACDURO. Clostridioides difficile- associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs. If CDAD is suspected or confirmed, the risk/benefit of continuing treatment with XACDURO should be assessed. Prescribing XACDURO in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Adverse Reactions: The most common adverse reactions reported in >10% of patients treated with XACDURO were liver test abnormalities (19%), diarrhea (17%), anemia (13%), and hypokalemia (12%). To report SUSPECTED ADVERSE REACTIONS, contact Innoviva Specialty Therapeutics, Inc. at 1-800-651-3861 or FDA at 1-800-FDA-1088 or . Before administering, please see the Full Prescribing Information for XACDURO . About Innoviva Specialty Therapeutics Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., is focused on delivering innovative therapies in critical care and infectious disease. Innoviva Specialty Therapeutics’ products, through its affiliates, include GIAPREZA ® (angiotensin II), XERAVA ® (eravacycline), XACDURO ® (sulbactam for injection; durlobactam for injection), and NUZOLVENCE ® (zoliflodacin). Innoviva Specialty Therapeutics also markets ZEVTERA (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the U.S. through an exclusive license from Basilea Pharmaceutica International Ltd, Allschwil. For more information about Innoviva Specialty Therapeutics, please visit . Forward Looking Statements This press release contains certain “forward-looking” statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. The words “anticipate”, “expect”, “goal”, “intend”, “objective”, “opportunity”, “plan”, “potential”, “target” and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties, and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of RELVAR ® /BREO ® ELLIPTA ® , ANORO ® ELLIPTA ® , GIAPREZA ® , XERAVA ® , XACDURO ® , ZEVTERA ® and NUZOLVENCE ® in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva’s growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to shareholders; the development of the LYNX ® platform; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the timing, manner and amount of capital deployment, including potential capital returns to stockholders; and risks related to the Company’s growth strategy. Other risks affecting Innoviva are described under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in Innoviva’s Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Reports on Form 10-Q, which are on the Securities and Exchange Commission (“SEC”) and available on the SEC’s website at . Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward looking statements on account of new information, future events or otherwise, except as required by law. ANORO ® , RELVAR ® and BREO ® are trademarks of the GSK group of companies. ZEVTERA is a trademark of Basilea Pharmaceutica International AG, Allschwil. 1 Lavrinenko (2021) Antibiotics 2 Rojas (2026) Antibiotics 3 WHO Bacterial Priority Pathogens List (2024) Contacts Investor and media contact Irwin Tendler Head of Investor Relations Executive Director, Corporate Development investors.relations@inva.com

28 May 2026

·www.biospace.com

Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, May 28, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, awarded USD 13.3 million to Basilea to continue the development of Basilea’s novel oral antibiotic ceftibuten-ledaborbactam etzadroxil, a beta-lactam/beta-lactamase inhibitor (BL/BLI) combination, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. David Veitch, Chief Executive Officer of Basilea, said: “Basilea is proud to be developing ceftibuten-ledaborbactam in partnership with BARDA. This funding helps us to further advance this novel antibiotic, including the preparation of the clinical phase 3 program. By advancing this promising candidate, we are potentially addressing the critical unmet need for the oral treatment of cUTIs caused by multidrug-resistant Gram-negative bacteria.” After the current tranche of USD 13.3 million, a total of USD 25 million have been committed by BARDA. The contract [ 1] could provide up to USD 133 million of additional non-dilutive funding. About beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations Many Gram-negative bacteria express enzymes such as extended spectrum beta-lactamases (ESBL) that confer resistance against commonly used antibiotics. Beta-lactamase inhibitors block these enzymes and restore the activity of beta-lactam antibiotics against initially resistant Gram-negative bacteria, therefore BL/BLI combinations are an important addition to the armamentarium for the treatment of infections caused by multidrug-resistant bacterial pathogens. About ceftibuten-ledaborbactam etzadroxil Ledaborbactam etzadroxil is the orally bioavailable prodrug of ledaborbactam, a novel broad-spectrum boronic acid beta-lactamase inhibitor, which is being developed in combination with ceftibuten, an oral cephalosporin antibiotic, which is approved in the US for the treatment of upper and lower respiratory tract infections and for urinary tract infections outside the US. In vitro and in vivo studies demonstrated that ledaborbactam etzadroxil restores the activity of ceftibuten against strains of Enterobacterales expressing Ambler class A extended spectrum beta-lactamases (ESBLs), class C cephalosporinases, and class A and D carbapenemases (KPC and OXA-48, respectively) as well as multidrug-resistant (MDR) Enterobacterales. [ 2 ] Ceftibuten-ledaborbactam etzadroxil has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the US Food and Drug Administration (FDA) for cUTI and uncomplicated urinary tract infections. Ceftibuten-ledaborbactam etzadroxil is an investigational drug and is not yet approved in any country for commercial use. About complicated urinary tract infections (cUTI) Complicated UTIs, which include pyelonephritis (kidney infections), are defined as urinary tract infections ascending from the bladder accompanied by local and systemic signs and symptoms and are one of the most common bacterial infections in hospital and community settings. Increasing resistance of bacteria causing complicated urinary tract infections has led to limited availability of effective oral antibiotic treatment options. [3] Currently, there are no approved oral beta-lactam or beta-lactam/beta-lactamase inhibitor combinations that are effective against Enterobacterales expressing Ambler class A ESBLs, class C cephalosporinases, and class A & D serine carbapenemases (KPC and OXA-48). About Basilea Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com. Disclaimer This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For further information, please contact: Peer Nils Schröder, PhD Head of Corporate Communications & Investor Relations Basilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b 4123 Allschwil Switzerland Phone +41 61 606 1102 E-mail media_relations@basilea.com investor_relations@basilea.com This ad hoc announcement can be downloaded from References This project has been funded in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50123C00050. J. A. Karlowsky, M. G. Wise, M. A. Hackel et al. Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018–2020 Global Surveillance Collection. Antimicrobial Agents and Chemotherapy 2022, Nov 15;66(11):e0093422 T. P. Lodise, T. Chopra, B. H. Nathanson et al. Epidemiology of Complicated Urinary Tract Infections due to Enterobacterales Among Adult Patients Presenting in Emergency Departments Across the United States. Open Forum Infectious Diseases 2022, Jun 24;9(7):ofac315. Attachment Ad hoc release

100 Deals associated with Amoxicillin/Clavulanate Potassium

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J01CR02	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bone and joint infections	Canada	Sandoz Canada, Inc.	28 Jan 2020
Genital Diseases, Female	Canada	Sandoz Canada, Inc.	28 Jan 2020
Intraabdominal Infections	Canada	Sandoz Canada, Inc.	28 Jan 2020
Severe infection	Canada	Sandoz Canada, Inc.	28 Jan 2020
Skin structures and soft tissue infections	Canada	Sandoz Canada, Inc.	28 Jan 2020
Acute bacterial sinusitis	United States	USAntibiotics	25 Sep 2002
Bronchitis, Chronic	Australia	Aspen Pharmacare Australia Pty Ltd.	08 Jan 1998
Community Acquired Pneumonia	Australia	Aspen Pharmacare Australia Pty Ltd.	08 Jan 1998
Acute Bronchitis	Japan	GlaxoSmithKline KK	01 Aug 1988
Pharyngitis	Japan	GlaxoSmithKline KK	01 Aug 1988
Tonsillitis	Japan	GlaxoSmithKline KK	01 Aug 1988
Cystitis	Japan	GlaxoSmithKline KK	29 Jul 1985
Gonorrhea	Japan	GlaxoSmithKline KK	29 Jul 1985
Intrauterine infection	Japan	GlaxoSmithKline KK	29 Jul 1985
Lymphadenitis	Japan	GlaxoSmithKline KK	29 Jul 1985
Non-complicated skin and skin structure infection	Japan	GlaxoSmithKline KK	29 Jul 1985
Pyelonephritis	Japan	GlaxoSmithKline KK	29 Jul 1985
Pyoderma	Japan	GlaxoSmithKline KK	29 Jul 1985
respiratory tract; infection, chronic	Japan	GlaxoSmithKline KK	29 Jul 1985
Bacterial Infections	United States	USAntibiotics	22 Jul 1985

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute sinusitis	Phase 3	Japan	GSK Plc	30 Aug 2013
Acute pyelonephritis	Phase 2	China	Xiangbei Weierman Pharmaceutical Co., Ltd.	10 Feb 2023
Suppuration	Phase 2	China	Shandong Teruilin Medicine Technology Development Co., Ltd.	19 May 2015
Genitourinary tract infection	Phase 2	China	Suzhou Erye Pharmaceutical Co., Ltd.	15 May 2013
Suppurative tonsillitis	Phase 2	China	Suzhou Erye Pharmaceutical Co., Ltd.	15 May 2013
Acute otitis media	Phase 1	China	Zhongshan Lienpu Pharmaceutical Co., Ltd	25 Apr 2024
Cellulitis	Phase 1	China	Zhongshan Lienpu Pharmaceutical Co., Ltd	25 Apr 2024
Osteomyelitis	Phase 1	China	Zhongshan Lienpu Pharmaceutical Co., Ltd	25 Apr 2024
Biliary tract infection	IND Approval	China	Guangdong Wonterfull ITD PharmaceuticalCo.,Ltd.	04 Jun 2026
Dental abscess	IND Approval	China	Guangdong Wonterfull ITD PharmaceuticalCo.,Ltd.	04 Jun 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05977868 (COPAT, CTgov)	Phase 4	Bone and joint infections \| Genitourinary tract infection \| Infection of digestive system ... View more	94	cefalexin+levofloxacin+Amoxicillin+doxycycline+delafloxacin+amoxicillin-clavulanate+linezolid+ciprofloxacin+cefpodoxime+cefadroxil (Group 1 (Experimental))	lqkdjaqkcu = ftekaozrai hwsqhxetqz (urssqoutst, yypvjhyvxy - lghcdrhtct) View more	-	26 Aug 2025
				cefazolin+ceftazidime-avibactam+dalbavancin+ampicillin-sulbactam+ceftaroline+ceftazidime+Ampicillin+cefepime+daptomycin+ertapenem (Group 2 (Control))	lqkdjaqkcu = ejtupndwxg hwsqhxetqz (urssqoutst, gvxugfalan - isosogpptd) View more
NCT02570347 (Pubmed \| BMJ Open)	Phase 4	Snake Bites	66	Clinically directed initiation of amoxicillin-clavulanate	fowbgzhcoj(jkpbgqurwp) = zhhoeapore jwapmwvwqa (uwsddzdrve )	Negative	01 Jun 2025
				Routine use of amoxicillin-clavulanate	fowbgzhcoj(jkpbgqurwp) = szzedxfece jwapmwvwqa (uwsddzdrve ) View more
NCT04414722 (OURBIOTIC, CTgov)	Early Phase 1	Diarrhea	118	BB-12+Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet (Concurrent BB-12 Yogurt and Amoxicillin-clavulanate)	wpnwkrcqba(wtllotizdf) = yemkkvenop zdeyhnpeqf (tzsexugdpu, xsexabigfy - wbjpljeaps) View more	-	25 Feb 2025
				BB-12+Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet (BB-12 Yogurt Taken 4 Hours After Amoxicillin-clavulanate)	wpnwkrcqba(wtllotizdf) = zbthjxbwwt zdeyhnpeqf (tzsexugdpu, wttiavdeka - ezwqvrnlya) View more
NCT05753735 (CTgov)	Phase 2	Pancreatic Fistula	3	Piperacillin/Tazobactam (Standard Perioperative Antibiotics)	ybfernwawt(fveumvkqph) = ietqefmtqr pycenidsyh (novyklnzdr, tjdwqlljal - cqrbhsqqnu) View more	-	24 Sep 2024
				Piperacillin/Tazobactam+Amoxicillin/ Clavulanic acid (Extended Antibiotic Prophylaxis)	lhduajcwei = ykekflbpxh lkeplhftah (hixuomptcr, ysnfzpvoiv - blzgexokfz) View more
NCT04600752 (CTgov)	Phase 4	Acute otitis media \| Acute sinusitis \| Respiratory Tract Infections	310	Augmentin (ES)-600 (Participants With Acute Otitis Media (AOM) Receiving Augmentin (ES)-600)	yfyyocwthr = ispzgaxffm ddpjijlhem (kexnzfqtyo, pnassyzilk - pqhfylhxps) View more	-	25 Apr 2024
				Augmentin (ES)-600 (Participants With Acute Bacterial Rhinosinusitis (ABRS) Receiving Augmentin (ES)-600)	yfyyocwthr = dhxebynbpr ddpjijlhem (kexnzfqtyo, okwiuxdnhw - visnojqpqd) View more
NCT03795194 (CTgov)	Phase 4	Abscess \| Appendicitis	7	ampicillin/clavulanate (8-day)	kpgvawcqtu(hylpmuvvxh) = tgvvanevez ocwqugzcri (wxnhicohvw, fpgheacdve - jjlrambkqg) View more	-	08 Mar 2024
				ampicillin/clavulanate (4-day)	kpgvawcqtu(hylpmuvvxh) = cbesivlgzp ocwqugzcri (wxnhicohvw, chnhvmxizp - zxsttxbqej) View more
ISRCTN47727811 (Pubmed \| Antimicrob Resist Infect Control)	Not Applicable	-	6,207	Cefuroxime plus metronidazole	ocytqitjlu(xnscpoyscm) = tbocobieba gwnfkstgut (vqkxnhpkov )	Positive	25 Sep 2023
				Amoxicillin/clavulanic acid	ocytqitjlu(xnscpoyscm) = xcnjmdhufi gwnfkstgut (vqkxnhpkov )
NCT03174184 (COMRADE, CTgov)	Phase 2	Pulmonary Tuberculosis	112	MEROPENEM 2 grams TID+Rifampin+Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet (Rifampin Resistant A)	acjyvwukte(wphohkjerr) = pgkufxxlau jludbmyccj (lauhjtptuz, nzdupsodap - konigvivcy) View more	-	19 Jul 2023
				MEROPENEM 2 grams TID+Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet (Rifampin Resistant B)	acjyvwukte(wphohkjerr) = pzlbkcbmhe jludbmyccj (lauhjtptuz, xvhturzrkz - ccnduabkyj) View more
NCT02554383 (CTgov)	Phase 3	Acute sinusitis	515	Amoxicillin-clavulanate (Amoxicillin-clavulanate)	zlbiddfcra(vybndqueaa) = rgbatlnxgk fepcoknwec (mvnbqcocmc, 7.8) View more	-	08 Jun 2023
				Placebo (Placebo)	zlbiddfcra(vybndqueaa) = omrmamwwfz fepcoknwec (mvnbqcocmc, 7.6) View more
NCT02517099 (PrIGMa, CTgov)	Phase 2	Asthma \| Inflammation \| Infectious Diseases	60	Beclometasone+Azithromycin+Co-amoxiclav (Pathological Phenotype)	bonejyndrx(yctkjvvdvo) = xhzkabekgi axutmbfiaf (mozuzxlitr, yqwtpdjulm - slyhnbkfmb) View more	-	06 Mar 2023
				Beclometasone+Azithromycin+Co-amoxiclav (Clinical Guidelines)	bonejyndrx(yctkjvvdvo) = kbmzjbclnl axutmbfiaf (mozuzxlitr, xyawgcpufe - zpfijejugy) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis